SHANG.FOS.PHARM.GR.H YC 1 Cash Flow Quality Index
SHANG.FOS.PHARM.GR.H YC 1 cash flow quality index. SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Cash Flow Quality Index of 1.55x as of December 2025. Operating cash flow of €5.21 Billion exceeds net income of €3.37 Billion, indicating high earnings quality where cash backs reported profits. See 08HH FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Cash flow quality index of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. Historical Cash Flow Quality Index for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 08HH cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow Quality Index by Year (2021–2025)
SHANG.FOS.PHARM.GR.H YC 1 cash flow quality index by year from 2021 to 2025. Year-by-year earnings quality comparison for SHANG.FOS.PHARM.GR.H YC 1. For the full cash flow conversion analysis, see cash efficiency ratio of SHANG.FOS.PHARM.GR.H YC 1.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.55x | €5.21 Billion | €3.37 Billion | ▼ -4.3% |
| 2024 | 1.62x | €4.48 Billion | €2.77 Billion | ▲ +13.6% |
| 2023 | 1.42x | €3.41 Billion | €2.40 Billion | ▲ +26.1% |
| 2022 | 1.13x | €4.22 Billion | €3.74 Billion | ▲ +35.7% |
| 2021 | 0.83x | €3.94 Billion | €4.74 Billion | — |